A synthetic pentasaccharide for the prevention of deep-vein thrombosis after total hip replacement.
about
New anticoagulants for the prevention and treatment of venous thromboembolismVenous thromboembolism deserves your attention.Neuraxial and peripheral nerve blocks in patients taking anticoagulant or thromboprophylactic drugs: challenges and solutionsSuperficial thrombophlebitis and low-molecular-weight heparinsReview of fondaparinux sodium injection for the prevention of venous thromboembolism in patients undergoing surgeryFondaparinux in the management of patients with ST-elevation acute myocardial infarctionVenous thromboembolic prophylaxis in hospitalized medical patients.Emerging anticoagulant and thrombolytic drugs.Essentials of anticoagulation in hemodialysis.Fondaparinux for the treatment of acute heparin-induced thrombocytopenia: a single-center experience.Fondaparinux sodium in the prophylaxis and treatment of deep vein thrombosis and pulmonary embolism.Pentasaccharides for the prevention of venous thromboembolism.Fondaparinux: a synthetic heparin pentasaccharide as a new antithrombotic agent.Dalteparin sodium.Oral, direct Factor Xa inhibition with BAY 59-7939 for the prevention of venous thromboembolism after total hip replacement.Fondaparinux versus enoxaparin for the prevention of venous thromboembolism.The role of thrombin inhibition during percutaneous coronary intervention.Selective factor Xa inhibition improves efficacy of venous thromboembolism prophylaxis in orthopedic surgery.Short- and long-acting synthetic pentasaccharides.Fondaparinux for prevention of venous thromboembolism in major orthopedic surgery.Direct thrombin inhibitors for anticoagulation.Fondaparinux: a Factor Xa inhibitor for antithrombotic therapy.Evolving concepts in the treatment of venous thromboembolism: the role of factor Xa inhibitors.Current concepts for the prevention of venous thromboembolism.From heparins to factor Xa inhibitors and beyond.Rationale for the use of antifactor Xa in the treatment and prevention of venous and arterial thromboembolic events.Fondaparinux: an update on new study results.The safety of fondaparinux for the prevention and treatment of venous thromboembolism.Short- and long-acting synthetic pentasaccharides as antithrombotic agents.Anticoagulation via anti-Factor Xa inhibition.Fondaparinux prevents venous thromboembolism after joint replacement surgery in Japanese patients.Efficacy and safety of fondaparinux in patients with acute coronary syndromes.Practical management of new oral anticoagulants after total hip or total knee arthroplasty.Clinical efficacy and safety of fondaparinux in the prevention and treatment of venous and arterial thrombosis.Case files of the Medical Toxicology Fellowship at Banner Good Samaritan Medical Center in Phoenix, AZ: a non-warfarin anticoagulant overdose.Massive hemoptysis in a patient with pulmonary embolism, a real therapeutic conundrum.Laboratory assessment of new anticoagulants.New anticoagulants: how to deal with treatment failure and bleeding complications.The efficacy and safety of pharmacological prophylaxis of venous thromboembolism following elective knee or hip replacement: systematic review and network meta-analysis.Recent insights on biochemical and molecular basis for developing antihaemostatic agents: A review
P2860
Q24681351-CA9ECDD2-68DA-4CD5-B4AE-6642C53CD9EDQ24797416-61832E4B-5B34-457F-88B6-980186FA4248Q26782931-11A56E7C-CFDB-4573-A013-FA1DB432AA2CQ28194366-3100CBD7-BEE9-4A67-B862-6C8ABE4F36FBQ28219412-01A00E4A-175F-4269-8179-FBFCD1DEA835Q28219415-1A48A3D5-ED4B-4C88-AD0E-F406908ABFA2Q33358712-FCC6FE11-9D7A-4FAE-B54B-F09792CAD48CQ33367019-59ED1783-9CCC-40EF-A07A-74E5D5F97395Q33374743-488D07A2-B41B-424E-AEA9-4E2ACDDB167BQ33386621-2B03F043-0EF2-4AD9-B448-941302D432D6Q33389966-35E2D59E-F6A4-48D2-8C2C-344B12A3F81AQ33436419-0D9E044E-2BAF-4711-829F-D6697110B905Q34116036-457C0748-79F0-4A1E-968B-CF47A189FC5AQ34390254-D8398527-F813-475D-AC80-210A0BDD54BBQ34564159-37B77EC3-D52E-41E6-A75D-594959EEF6E3Q34588736-D8E5C743-45CF-496B-8D2A-65DA9416C0CDQ34685608-41571C40-6C48-4208-9A76-3478997C02E9Q35160253-94A15B92-7E4D-4860-9C6A-DDE268349F78Q35219377-45536979-2A69-483E-85F4-43A53EB73D6AQ35562634-130A6586-BF2D-478F-AE94-77249F3162A8Q35638059-86D532DF-F500-40CC-8163-FA115B8DB7A5Q35784074-BA59BBE5-7168-4B8B-9FF5-9959A4BA3478Q35866092-C5A68821-A788-44BE-A5C2-529D2B510239Q36034723-46C1511A-7D78-4BE2-BC06-817367BF05D2Q36034728-02B13C40-5971-4EAA-BF2A-CD3E90694A0AQ36034733-F0DFAAB4-3B60-46BE-80F6-78174CA6DB93Q36034740-90B765D6-456C-4D03-B72C-593F5E885143Q36191034-58B13044-4C1A-4293-AA6C-A84A56950628Q36196467-F1228180-5E1C-4568-BD60-F3F89F037804Q36458159-7CAD6087-C2EB-48CC-BE1C-E25482716601Q36867390-321B9E12-D85F-46AB-9671-0555F625B50CQ37012898-B6DB6753-68C6-48D7-9340-96E525F9FEF1Q37338120-1E650DD1-82AE-4B7B-BDAC-7656ECCCE00FQ37608455-4CC1229F-3F2F-4B52-A9B9-A38A682D0276Q37624544-CDD18246-3A6D-4EFB-BE2C-9AE1405D8FD4Q37683335-02722879-DF36-4398-9926-93B6A3109F9FQ37834646-630FD07A-0800-4C08-9615-0776D5EA293CQ37900670-057290DF-101D-4962-8EB4-77B52E1E3E65Q37990316-F5DD2C80-D32B-4BDF-9CEC-08B9D9145126Q38056119-452FDECA-AD68-43CB-94C6-5FE3C9DD6F4E
P2860
A synthetic pentasaccharide for the prevention of deep-vein thrombosis after total hip replacement.
description
2001 nî lūn-bûn
@nan
2001 թուականի Մարտին հրատարակուած գիտական յօդուած
@hyw
2001 թվականի մարտին հրատարակված գիտական հոդված
@hy
2001年の論文
@ja
2001年論文
@yue
2001年論文
@zh-hant
2001年論文
@zh-hk
2001年論文
@zh-mo
2001年論文
@zh-tw
2001年论文
@wuu
name
A synthetic pentasaccharide fo ...... s after total hip replacement.
@ast
A synthetic pentasaccharide fo ...... s after total hip replacement.
@en
type
label
A synthetic pentasaccharide fo ...... s after total hip replacement.
@ast
A synthetic pentasaccharide fo ...... s after total hip replacement.
@en
prefLabel
A synthetic pentasaccharide fo ...... s after total hip replacement.
@ast
A synthetic pentasaccharide fo ...... s after total hip replacement.
@en
P2093
P1476
A synthetic pentasaccharide fo ...... s after total hip replacement.
@en
P2093
A G Turpie
A S Gallus
Pentasaccharide Investigators
P304
P356
10.1056/NEJM200103013440901
P407
P577
2001-03-01T00:00:00Z